PAVmed, Inc. PAVM 深 沪
等待开盘 02-07 09:30:00 美东时间
10.80
+0.220
+2.08%
华盛通- 最 高28.44
- 今 开10.83
- 成交量 27.97万股
- 最 低 0.21
- 昨 收 10.58
- 总市值 95.01万
- 52周最高 28.44
- 市盈率 静 --
- 换手率 317.92%
- 52周最低 0.21
- 委 比 -21.57%
- 总股本 8.80万
- 历史最高 28.44
- 量 比 0.65
- 振 幅 266.82%
- 历史最低 0.09
- 每 手 1
- 风险率 2.38%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Is PAVmed Stock Skyrocketing Wednesday?
Pavmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for its cancer prevention test.
01-22 00:22
Dow Surges 300 Points; Netflix Shares Fall After Q4 Results
U.S. stocks traded higher this morning, with the Dow Jones index gaining around...
01-21 23:05
Earnings Scheduled For November 13, 2025
Companies Reporting Before The Bell • Edgewell Personal Care (NYSE:EPC) is proj...
2025-11-13 19:11
Lucid Diagnostics And Front Line Mobile Health Forge Partnership To Enhance Esophageal Cancer Screening Among First Responders
Collaboration aims to enhance early detection of esophageal cancer in at-risk patients through strategic co-marketing initiatives serving firefighters Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of P...
2024-09-03 19:57
Lucid Diagnostics Announces Publication Of Analytical Validation Study Of EsoGuard For Early Detection Of Esophageal Precancer And Cancer In The Peer-Reviewed Journal Diagnostics
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (NASDAQ:PAVM), today announced the peer-reviewed publication of an analytical validation study of its EsoGuard® Esophageal DNA test for the ...
2024-08-20 20:18
